Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.58 - $2.51 $30,898 - $49,085
19,556 New
19,556 $34,000
Q4 2023

Feb 09, 2024

BUY
$1.59 - $3.85 $38,574 - $93,404
24,261 New
24,261 $81,000
Q2 2023

Aug 14, 2023

SELL
$3.79 - $8.3 $101,265 - $221,767
-26,719 Reduced 63.0%
15,694 $67,000
Q1 2023

May 12, 2023

BUY
$5.89 - $10.52 $249,812 - $446,184
42,413 New
42,413 $290,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $157,661 - $304,987
-21,989 Reduced 51.75%
20,500 $197,000
Q2 2022

Aug 12, 2022

BUY
$5.86 - $13.23 $248,985 - $562,129
42,489 New
42,489 $308,000
Q1 2022

May 16, 2022

SELL
$10.92 - $16.41 $267,354 - $401,766
-24,483 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.81 - $18.99 $387,076 - $464,932
24,483 New
24,483 $391,000
Q2 2021

Aug 13, 2021

SELL
$12.95 - $15.41 $517,015 - $615,228
-39,924 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$14.42 - $21.39 $575,704 - $853,974
39,924 New
39,924 $583,000
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $455,785 - $605,187
-31,586 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$11.67 - $22.53 $103,302 - $199,435
8,852 Added 38.94%
31,586 $512,000
Q4 2019

Feb 14, 2020

BUY
$16.33 - $21.37 $91,545 - $119,800
5,606 Added 32.73%
22,734 $409,000
Q3 2019

Nov 14, 2019

BUY
$16.3 - $23.37 $279,186 - $400,281
17,128 New
17,128 $347,000
Q2 2019

Aug 14, 2019

SELL
$13.1 - $22.1 $283,353 - $478,023
-21,630 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$8.38 - $15.5 $66,000 - $122,078
7,876 Added 57.26%
21,630 $295,000
Q4 2018

Feb 13, 2019

SELL
$8.65 - $16.28 $186,744 - $351,468
-21,589 Reduced 61.08%
13,754 $125,000
Q3 2018

Nov 14, 2018

BUY
$14.45 - $20.25 $311,224 - $436,144
21,538 Added 156.02%
35,343 $583,000
Q2 2018

Aug 14, 2018

BUY
$10.25 - $17.45 $141,501 - $240,897
13,805 New
13,805 $193,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.